ARS Pharmaceuticals, Inc.
Edit

ARS Pharmaceuticals, Inc.

https://ars-pharma.com/
Last activity: 21.03.2024
Active
Categories: DevelopmentFoodTechITMedtechProductTechnology
Our mission at ARS Pharmaceuticals is to provide at-risk patients and their families better protection from severe allergic reactions. We are developing a product that patients and their caregivers can use without anxiety or hesitation, confident in the effectiveness of the both product and the ability to administer it.

We are developing ARS-1, a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient and more reliable for patients and loved ones at-risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.
Followers
196
Followers
278
Mentions
53
Location: United States, California, San Diego
Employees: 11-50
Total raised: $55M
Founded date: 2015
Twitter
LinkedIn

Investors 3

DateNameWebsite
01.09.2021RA Capital...racap.com
30.08.2023OrbiMedorbimed.co...
15.09.2021SR Onesrone.com

Funding Rounds 1

DateSeriesAmountInvestors
14.10.2021Series D$55M-

Mentions in press and media 53

DateTitleDescription
21.03.2024ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsPreparing to submit response to the FDA’s CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessment...
11.05.2023First epinephrine nasal spray clears key FDA hurdle, promising needle-free alternativeA committee of the Food and Drug Administration's outside advisers voted Thursday in favor of an epinephrine nasal spray product, clearing a key hurdle for what could soon be the first needle-free option for treating severe allergic reactio...
01.08.2022ARS, Seattle Firm to MergeARS Pharmaceuticals, Inc. is ramped up and ready to go for its expected commercial launch of neffy – an epinephrine nasal inhaler for treating severe allergic reactions. Richard Lowenthal CEO ARS Pharmaceuticals, Inc. On July 21, ARS announ...
14.10.2021ARS Pharmaceuticals Raises Series D Funding Round Worth $55M To Advance Neffy One of the Products that ARS is Developing-
14.10.2021ARS Pharma Secures $55M in Series D Funding that will be used to further develop one of their major products, Neffy-
13.10.2021ARS Pharmaceuticals Raises Series D Funding Round Worth $55M To Advance Neffy One of the Products that ARS is Developing-
13.10.2021ARS Pharma Secures $55M in Series D Funding that will be used to further develop one of their major products, Neffy-
11.10.2021ARS Pharmaceuticals Raises Series D Funding Round Worth $55M To Advance Neffy One of the Products that ARS is Developing-
11.10.2021ARS Pharma Secures $55M in Series D Funding that will be used to further develop one of their major products, Neffy-
10.10.2021ARS Pharmaceuticals Raises Series D Funding Round Worth $55M To Advance Neffy One of the Products that ARS is Developing-
Show more

Reviews 0

Sign up to leave a review

Sign up Log In